Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

Former Pfizer Inc. executives Ian Read and Frank D’Amelio have decided “not to be involved” in Starboard Value’s activist ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...